AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

Study Summary

The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2.

Conditions

Gastric Cancer Gastroesophageal Junction Cancer Biliary Tract Cancer Pancreatic Ductal Adenocarcinoma

Interventions / Drugs

AZD0901 5-Fluorouracil Leucovorin l-leucovorin Irinotecan Nanoliposomal Irinotecan Gemcitabine

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment224 participants

Primary Completion—

Lead SponsorAstraZeneca

Data Retrieved2026-04-11 02:55:19.910377+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.